Healthcare Industry News:  schizophrenia 

Biopharmaceuticals Licensing Neurology

 News Release - February 6, 2006

Targacept Announces Early Completion of Hart-Scott-Rodino Waiting Period for Agreement With AstraZeneca

Targacept Receives $10 Million Payment

WINSTON-SALEM, N.C., Feb. 6 (HSMN NewsFeed) -- Targacept, Inc. announced today that it has received notification of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to its agreement with AstraZeneca AB, and the agreement has become effective. As previously announced, Targacept and AstraZeneca entered into an exclusive global license and research collaboration agreement in December 2005 for the development and commercialization of Targacept's proprietary compound TC-1734 (AZD3480) to treat Alzheimer's disease, cognitive deficits in schizophrenia and other cognitive disorders. The agreement also provides for a four-year research collaboration under which Targacept will utilize its proprietary drug discovery technology known as Pentad(TM) to discover additional compounds. With effectiveness of the agreement, Targacept has received the $10 million initial payment from AstraZeneca.

About Targacept

Targacept is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the central nervous system by selectively targeting neuronal nicotinic receptors, or NNRs. Targacept is located in Winston-Salem, North Carolina.


Source: Targacept

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.